Timothy Illidge, BSc, PhD, MRCP, FRCR, FRCPath, from University of Manchester, Manchester, UK, provides an overview of immunomodulatory treatment of lymphomas at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Lymphoma treatment appears to be evolving fast. High response rates have been seen in Hodgkin’s lymphoma and so focus has moved on to looking at immune checkpoint blockade in other non-Hodgkin’s lymphomas, where achieving a good response rate has proven to be more difficult. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.